67376-72-1

Basic information

• Product Name: (2R,3S)-(-)-3,4-DIMETHYL-5,7-DIOXO-2-PHENYLPERHYDRO-1,4-OXAZEPINE)
• Synonyms: (2R,3S)-(-)-3,4-DIMETHYL-5,7-DIOXO-2-PHENYLPERHYDRO-1,4-OXAZEPINE)
• CAS NO: 67376-72-1
• Molecular Formula: C₁₃H₁₅NO₃
• Molecular Weight: 233.26
• Mol File: 67376-72-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 457.069°C at 760 mmHg
• Flash Point: 230.228°C
• Appearance: /
• Density: 1.146g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.525
• CAS DataBase Reference: (2R,3S)-(-)-3,4-DIMETHYL-5,7-DIOXO-2-PHENYLPERHYDRO-1,4-OXAZEPINE)(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,3S)-(-)-3,4-DIMETHYL-5,7-DIOXO-2-PHENYLPERHYDRO-1,4-OXAZEPINE)(67376-72-1)
• EPA Substance Registry System: (2R,3S)-(-)-3,4-DIMETHYL-5,7-DIOXO-2-PHENYLPERHYDRO-1,4-OXAZEPINE)(67376-72-1)

Safety Data

• Hazardous Substances Data: 67376-72-1(Hazardous Substances Data)

Usage

Description

(2R,3S)-(-)-3,4-DIMETHYL-5,7-DIOXO-2-PHENYLPERHYDRO-1,4-OXAZEPINE is a stereoisomer of the oxazepine molecule, characterized by its molecular formula C15H17NO3 and a molecular weight of 259.30 g/mol. This cyclic organic compound features a six-membered ring with oxygen and nitrogen atoms, and is recognized for its potential pharmacological properties. It is commonly utilized in pharmaceutical research and development as a promising drug candidate, although further studies and testing are required to ascertain its specific applications and therapeutic uses.

Uses

Used in Pharmaceutical Research and Development:
(2R,3S)-(-)-3,4-DIMETHYL-5,7-DIOXO-2-PHENYLPERHYDRO-1,4-OXAZEPINE is employed as a potential drug candidate in pharmaceutical research and development due to its pharmacological properties. Its unique molecular structure and stereochemistry make it a valuable compound for exploring new therapeutic avenues and developing innovative treatments for various medical conditions. Further studies are necessary to fully understand its potential applications and to optimize its use in the pharmaceutical industry.

InChI:InChI=1/C13H15NO3/c1-9-13(10-6-4-3-5-7-10)17-12(16)8-11(15)14(9)2/h3-7,9,13H,8H2,1-2H3/t9-,13-/m0/s1

Upstream product

• 16695-14-0 Malonic acid monomethyl ester 
• 299-42-3 ephedrine 
• 108-59-8 malonic acid dimethyl ester 

Downstream Products

• 128735-66-0 (4R,5S)-5-((2R,3S,6S)-3,4-Dimethyl-5,7-dioxo-2-phenyl-[1,4]oxazepan-6-yl)-4-ethyl-2-hydroxy-3-oxo-cyclopent-1-enecarboxylic acid methyl ester 
• 74639-51-3 3-[(2R,3S)-3,4-Dimethyl-5,7-dioxo-2-phenyl-[1,4]oxazepan-(6E)-ylidenemethyl]-indole-1-carboxylic acid benzyl ester 
• 74639-51-3 3-[(2R,3S)-3,4-Dimethyl-5,7-dioxo-2-phenyl-[1,4]oxazepan-(6Z)-ylidenemethyl]-indole-1-carboxylic acid benzyl ester 
• 98720-23-1 (2R,3S)-6-[1-[3-Methoxy-2-(3-methyl-but-2-enyloxy)-phenyl]-meth-(E)-ylidene]-3,4-dimethyl-2-phenyl-[1,4]oxazepane-5,7-dione 
• 98720-23-1 (2R,3S)-6-[1-[3-Methoxy-2-(3-methyl-but-2-enyloxy)-phenyl]-meth-(Z)-ylidene]-3,4-dimethyl-2-phenyl-[1,4]oxazepane-5,7-dione 
• 98720-24-2 (2R,3S)-6-[1-[5-Bromo-2-(3-methyl-but-2-enyloxy)-phenyl]-meth-(Z)-ylidene]-3,4-dimethyl-2-phenyl-[1,4]oxazepane-5,7-dione 
• 98720-24-2 (2R,3S)-6-[1-[5-Bromo-2-(3-methyl-but-2-enyloxy)-phenyl]-meth-(E)-ylidene]-3,4-dimethyl-2-phenyl-[1,4]oxazepane-5,7-dione 
• 98720-25-3 (2R,3S)-6-[1-[3,5-Dichloro-2-(3-methyl-but-2-enyloxy)-phenyl]-meth-(Z)-ylidene]-3,4-dimethyl-2-phenyl-[1,4]oxazepane-5,7-dione 
• 98720-25-3 (2R,3S)-6-[1-[3,5-Dichloro-2-(3-methyl-but-2-enyloxy)-phenyl]-meth-(E)-ylidene]-3,4-dimethyl-2-phenyl-[1,4]oxazepane-5,7-dione 
• 65092-79-7 (2R)-6-(Z)-benzylidene-3c,4-dimethyl-2r-phenyl-[1,4]oxazepane-5,7-dione 
• 65092-79-7 (2R,3S)-3,4-Dimethyl-2-phenyl-6-[1-phenyl-meth-(E)-ylidene]-[1,4]oxazepane-5,7-dione 
• 738627-95-7 (2S,3S)-(E)-(2,2-dimethylpropylidene)-3,4-dimethyl-2-phenyl-[1,4]oxazepane-5,7-dione 
• 738628-02-9 (2S,3S)-(Z)-(2,2-dimethylpropylidene)-3,4-dimethyl-2-phenyl-[1,4]oxazepane-5,7-dione 
• 738628-05-2 (2R,3S)-6-((R)-1-Isopropyl-5-phenyl-pent-2-ynyl)-3,4-dimethyl-2-phenyl-[1,4]oxazepane-5,7-dione 

Relevant articles and documents

Asymmetric syntheses of a GPR40 receptor agonist via diastereoselective and enantioselective conjugate alkynylation

Two asymmetric methods to synthesize a potent GPR40 receptor agonist are reported. Both synthetic routes utilize readily available, inexpensive starting materials and reagents. The first route relies on a highly diastereoselective conjugate alkynylation of an ephedrine-derived oxazepanedione acceptor. The second route features the enantioselective alkynylation of a Meldrum's acid-derived acceptor mediated by a chiral zinc cinchonidine reagent.

Hochenantioselektive intramolekulare Hetero-Diels-Alder-Reaktionen zur Synthese enantiomerenreiner tricyclischer Lactone

-